Want to join the conversation?
For remainder of 2015, $ABBV sees revenue performance to be driven by strong growth from HUMIRA, global launch of interferon-free HCV treatment, and revenue growth in certain key products including Creon and Duodopa. IMBRUVICA, acquired through the acquisition of Pharmacyclics, will also be significant contributor to revenue growth in 2015.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.